Tower Research Capital (TRC)’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,814
| Closed | -$3.59K | – | 6384 |
|
|
2023
Q3 | $3.59K | Sell |
2,814
-13,003
| -82% | -$11.4K | ﹤0.01% | 4985 |
|
|
2023
Q2 | $5.16K | Buy |
15,817
+15,733
| +18,730% | +$5.64K | ﹤0.01% | 4856 |
|
|
2023
Q1 | $0 | Sell |
84
-14,949
| -99% | -$7.88K | ﹤0.01% | 6550 |
|
|
2022
Q4 | $8K | Sell |
15,033
-14,113
| -48% | -$8.95K | ﹤0.01% | 4502 |
|
|
2022
Q3 | $21K | Buy |
29,146
+27,034
| +1,280% | +$30.7K | ﹤0.01% | 3917 |
|
|
2022
Q2 | $2K | Buy |
2,112
+310
| +17% | +$395 | ﹤0.01% | 5653 |
|
|
2022
Q1 | $4K | Buy |
1,802
+1,729
| +2,368% | +$4.11K | ﹤0.01% | 5298 |
|
|
2021
Q4 | $0 | Buy |
+73
| New | +$270 | ﹤0.01% | 6764 |
|
|
2021
Q3 | – | Sell |
-23,194
| Closed | -$122K | – | 6343 |
|
|
2021
Q2 | $122K | Buy |
+23,194
| New | +$112K | ﹤0.01% | 2273 |
|
|
2020
Q3 | – | Sell |
-6,213
| Closed | -$21K | – | 5194 |
|
|
2020
Q2 | $21K | Buy |
+6,213
| New | +$29.4K | ﹤0.01% | 3663 |
|
|
2020
Q1 | – | Sell |
-4,250
| Closed | -$26K | – | 4146 |
|
|
2019
Q4 | $26K | Sell |
4,250
-1,298
| -23% | -$8.88K | ﹤0.01% | 1768 |
|
|
2019
Q3 | $42K | Buy |
5,548
+261
| +5% | +$2.94K | ﹤0.01% | 1929 |
|
|
2019
Q2 | $72K | Buy |
+5,287
| New | +$61K | ﹤0.01% | 1366 |
|
|
2019
Q1 | – | Sell |
-11,497
| Closed | -$35K | – | 4451 |
|
|
2018
Q4 | $35K | Buy |
11,497
+10,997
| +2,199% | +$60.2K | ﹤0.01% | 1539 |
|
|
2018
Q3 | $4K | Sell |
500
-2,325
| -82% | -$17.8K | ﹤0.01% | 3239 |
|
|
2018
Q2 | $28K | Sell |
2,825
-4,189
| -60% | -$42.9K | ﹤0.01% | 2219 |
|
|
2018
Q1 | $61K | Buy |
+7,014
| New | +$75.6K | 0.01% | 1569 |
|
|
2017
Q4 | – | Sell |
-3,913
| Closed | -$33K | – | 4167 |
|
|
2017
Q3 | $33K | Buy |
3,913
+3,828
| +4,504% | +$40.5K | ﹤0.01% | 2368 |
|
|
2017
Q2 | $1K | Sell |
85
-15
| -15% | -$298 | ﹤0.01% | 2536 |
|
|
2017
Q1 | $2K | Buy |
+100
| New | +$1.99K | ﹤0.01% | 2691 |
|
|
2016
Q3 | – | Sell |
-224
| Closed | -$2K | – | 4666 |
|
|
2016
Q2 | $2K | Buy |
+224
| New | +$1.88K | ﹤0.01% | 3997 |
|
|
2016
Q1 | – | Sell |
-62
| Closed | -$1K | – | 5151 |
|
|
2015
Q4 | $1K | Sell |
62
-138
| -69% | -$1.83K | ﹤0.01% | 4209 |
|
|
2015
Q3 | $3K | Buy |
+200
| New | +$4.91K | ﹤0.01% | 3193 |
|
Tower Research Capital (TRC)'s ZYNE Position: Q4 2023 in Review
Tower Research Capital (TRC) sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 2,814 shares — an estimated $3.59K sold.
Tower Research Capital (TRC) first reported a position in ZYNE in Q3 2015 and held it in 23 quarters. The position peaked at $122K in Q2 2021. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Tower Research Capital (TRC) reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,814 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $3.59K.
- Tower Research Capital (TRC) first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 23 quarters.
- Tower Research Capital (TRC)'s Zynerba Pharmaceuticals, Inc position peaked at $122K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.